Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by gldblvon Dec 18, 2013 11:50pm
240 Views
Post# 22021089

RE:RE:RE:Re etc. Spinco

RE:RE:RE:Re etc. SpincoSpinCo cash value is $0.39 because total outstanding # of shares will be around 25.5M.  In equivalent BRD value it is $0.039 because there are 230M shares.  The 0.1 multiplier.

Appart from that, I read a few about Goldfields because I was not around BRD back then.  Goldfields was moving forward until new discoveries pushed BRD to put all their energy on blackfox.  Goldfield has all the requirements in order to become a profitable mine and is not too far away from production.  Alot of work has already been done.  If POG can go back above $1400 we should see good value there.  Only challenge will be to find the money for capex. 

Desjardins has a buy on P with target price of $7.  I still think that this deal is better for P than for BRD.  However this should help unlock the potential of blackfox quite faster because we were short on cash and P has plenty.  They plan to spend alot on exploration.  By memory something around $30M per year.  So in the end it should still be good for us because things will move up faster.  We only need POG to stop going down and we should be ready for all the great NR this $30M exploration campaign will bring to us.  By looking at what has been done in the last 2 years it is obvious that there is alot of gold in that area.

Any body buying SAS (our neighbor) for potential futur buyout from P to extend surrounding territory ? I was hearing about BRD and SAS rumors prior to this buyout. 

GLTA
Bullboard Posts